Source: Times of India


WASHINGTON: Several hospitals in the US are using antimalarial drug hydroxychloroquine in the treatment of COVID-19 positive patients, a media report has said.


MDedge, a medical publication, on Friday reported that hydroxychloroquine (HCQ) is currently the first-line therapy and Tocilizumab the second-line medication for people hospitalized with polymerase chain reaction-confirmed COVID-19 infection in the Yale New Haven Health System, which operates hospitals across Connecticut.

See the medical publication here: https://www.mdedge.com/hematology-oncology/article/221558/coronavirus-updates/yales-covid-19-inpatient-protocol

“Hydroxychloroquine is first-line at Yale because in-vitro data shows potent inhibition of the virus and possible clinical benefit, which is about as good as evidence gets at the moment,” Indian-American cardiologist Nihar Desai told the medical publication.


“It’s cheap, it’s been used for decades, and people are relatively comfortable with it,” he added.

Yale New Haven Hospital, is almost half full with COVID-19 patients, at more than 400, the report said.


On US President Donald Trump’s request, India allowed the export of 50 million HCQ tablets to treat COVID-19 patients in America, the worst-hit country by the pandemic.


On Friday, US Food and Drug Administration gave emergency use authorization (EUA) for the use of investigational anti-viral Remdesivir for the treatment of COVID-19 patients.


HCQ was the first drug to receive EAU from FDA for the treatment of COVID-19 patients.


The US President has been an advocate of use of HCQ, which has reportedly cured patients in New York and several other place.


Reports indicate that the malaria drug has been effective during the initial phases of a person being infected by coronavirus but poses a danger to those having heart ailments.

See the original article here: https://timesofindia.indiatimes.com/world/us/several-us-hospitals-using-hcq-in-treatment-of-covid-19-patients-report/articleshow/75501008.cms

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

Stark madness to ban ivermectin

Buried in the note is the real reason for making ivermectin inaccessible – the fear that persons taking it ‘may elect not to be vaccinated as part of the national Covid-19 vaccination program’. This is outrageous. When someone is infected with Covid, it is too late to bother with vaccination. They need early treatment. To deny it to coerce them into accepting a vaccine, one of whose side-effects is death, is immoral.

Read More »

Australia’s TGA Bans GPs from Prescribing Ivermectin

Australia’s medicine and therapeutic regulatory, the Therapeutic Good Administration (TGA) recently took the gloves off with Ivermectin, the economical anti-parasitic drug associated with at least 63 completed clinical trials involving SARS-CoV-2, the virus behind COVID-19. Now TGA formally places a national prohibition on off-label prescribing of ivermectin to all general practitioners. A comparable move as to what TGA did with hydroxychloroquine in 2020. Clearly further evidence of tightening encroachment of the critically important doctor-patient treatment relationship allowing consent to medical treatment using off-label medications. Of course, this isn’t occurring in a vacuum—it’s part of an unfolding, integrated and what have the signs of a coordinated and orchestrated government action to stop any and all treatments other than those the government declares acceptable.

Read More »